Traws Pharma Inc. (NASDAQ: TRAW) on Wednesday shared interim data from an ongoing randomized, open-label Phase 2 with ratutrelvir, an investigational oral, ritonavir-free Mpro/3CL protease inhibitor.

INNSBRUCK, Austria, Dec. 9, 2025 /PRNewswire/ -- As cyberattacks continue to challenge even the most resilient organisations, the need for clear, trustworthy, and openly documented security testing ...

Consumers continued to flock to Costco (NASDAQ:COST), taking advantage of the warehouse store’s sizable bulk-rate savings fourth quarter results beating Wall Street’s expectations on nearly every ...

The iPhone 17 and iPhone 17 Pro both received facelifts for 2025. Here's how the specs of the two compare, and whether it is worth paying at least $300 more to go Pro. Each year, Apple brings out its ...

New computer simulations suggest the first magnetic fields that emerged after the Big Bang were much weaker than expected — containing the equivalent magnetic energy of a human brain. When you ...

BANGKOK, July 24 (Reuters) - Months of simmering tensions between Cambodia and Thailand exploded into armed conflict on Thursday, including the deployment of a Thai F-16 fighter jet, in the heaviest ...

Congressional Republicans approved President Donald Trump’s sweeping tax and spending cuts package, otherwise known as the “big, beautiful bill.” The House GOP ultimately passed the Senate’s ...

Pew Research Center conducted this study to continue tracking news consumption and trust across a wide range of specific news sources. We last published similar reports in 2020 (based on a 2019 survey ...

Most of us don’t appreciate where our problems sit on a scale from ordinary to tragic. One day your frustrations relate to impressing the family of your intended husband, or to the local school’s ...